Special Issue

Antibiotic Tolerance of Bacterial Biofilms

Message from the Guest Editor

While the emergence of bacterial strains resistant to antibiotics is increasingly threatening, we must not forget that bacteria all have a powerful and natural behavior: the ability to form biofilms. These biofilms, tolerant of 10 to 100 times the MIC of conventional antibiotics, are a major issue for public health. It is urgent to better decipher biofilms and develop antibiofilm strategies. Thus, better understanding of biofilms, how and why they are formed and in what environment, will allow a better development of adapted strategies (prevention, weakening, disruption, killing) to counter them. This Special Issue seeks manuscript submissions that further our understanding of biofilm tolerance to antibiotics, the involved mechanisms and the development of antibiofilm strategies. Potential topics include, but are not limited to:

- Biofilms mechanisms
- Identification of mechanims involved in antibiotic tolerance
- Identification of bacterial targets to fight agaisnt biofilm
- Antibiofilm molecules
- *In vitro* or *in vivo* biofilm models development

Guest Editor

Dr. Fany Reffuveille
Université de Reims Champagne-Ardenne, EA4691 BIOS lab, Reims, France

Deadline for manuscript submissions

closed (20 November 2020)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/36940

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI